Apeloa Pharmaceutical

What Apeloa Pharmaceutical does

Apeloa Pharmaceutical Co., Ltd. (普洛药业股份有限公司, Shenzhen Stock Exchange: 000739) is a vertically integrated Chinese pharmaceutical manufacturer founded in 1989 and headquartered in Hengdian, Dongyang, Zhejiang. Operating as a subsidiary of Hengdian Group (a diversified conglomerate with over 70 billion RMB in total assets), the company employs 5,001–10,000 staff, including 1,300+ R&D personnel, and is ranked 36th among China's pharmaceutical industrial enterprises, 2nd in China's chemical API exports, and 5th among China's small molecule CDMO providers.

The company operates four core business segments: (1) APIs and intermediates, spanning chemical synthesis and biological fermentation; (2) CDMO services providing end-to-end contract development and manufacturing for innovative drugs; (3) finished dosage form pharmaceuticals covering CNS, cardiovascular, anti-infective, and digestive therapeutic areas; and (4) medical aesthetic and cosmetic ingredients leveraging biosynthetic and peptide platforms. Underpinning these segments are advanced engineering platforms including flow chemistry, synthetic biology and biocatalysis, peptide synthesis (with GLP-1 analog capability), high-potency API manufacturing, oligonucleotide synthesis, bioconjugate development, controlled-release formulation, and crystal/particle engineering. Manufacturing has passed multiple FDA on-site inspections with zero defects, and the company holds EU GMP, WHO PQ, ISO 56005, and ISO/IEC 27001 certifications.

Revenue is generated primarily through B2B contracts with global pharmaceutical companies for API supply and CDMO services, supplemented by domestic distribution of finished dosage forms and sales of cosmetic/aesthetic ingredients to leading international cosmetics raw-material companies. Revenue exceeded 10 billion RMB in 2023 according to company disclosures. The customer base spans international and domestic pharmaceutical manufacturers, biotech innovators (Hionext, Hutchmed, Simcere, Zhejin), and consumer goods companies, served through direct enterprise sales, international trade exhibitions (CPHI Frankfurt, CPHI China), and domestic distribution networks. The company maintains international offices in Tokyo, Frankfurt, and Boston alongside its Chinese operations.

Name

Apeloa Pharmaceutical

Legal name

APELOA Pharmaceutical Co., Ltd.

Website

https://apeloa.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Apeloa Pharmaceutical is a vertically integrated Chinese pharmaceutical manufacturer (SSE: 000739) and Hengdian Group subsidiary that produces APIs/intermediates, provides end-to-end CDMO services, manufactures finished dosage forms, and supplies aesthetic/cosmetic ingredients to global pharmaceutical and consumer goods companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Active pharmaceutical ingredients
• Contract drug manufacturing
• Finished dosage forms
• Cosmetic peptide ingredients
• Pharmaceutical CDMO services

Headquarters

HQ city

Dongyang

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API) & Intermediates: Manufacturing and sales of active pharmaceutical ingredients and intermediates, serving global pharmaceutical companies. The company is ranked 2nd in China's API exports.
2. CDMO Services: Contract Development and Manufacturing Organization services providing end-to-end solutions from drug development through commercial manufacturing. Includes process development, clinical trial supply, and commercial production.
3. Finished Dosage Form (Drugs/Pharmaceuticals): Development and manufacturing of finished pharmaceutical products including tablets, capsules, injections, and topical formulations. Includes both prescription and OTC products.
4. Aesthetic & Cosmetic Ingredients: R&D, production and sales of medical aesthetic and cosmetic raw materials, leveraging advanced biosynthetic and peptide technology platforms.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Apeloa manufactures and sells active pharmaceutical ingredients (APIs) and intermediates, provides end-to-end Contract Development and Manufacturing Organization (CDMO) services for innovative drugs, develops finished dosage form pharmaceuticals (tablets, capsules, injections, topicals), and produces medical-aesthetic and cosmetic ingredients. The company combines chemical synthesis and biological fermentation platforms to serve global pharmaceutical customers from early-stage development through commercial production.

Product overview

Apeloa Pharmaceutical operates as an integrated pharmaceutical manufacturing services company with four core business segments: Active Pharmaceutical Ingredients (API) & Intermediates, CDMO (Contract Development and Manufacturing Organization) services for innovative drugs, Finished Dosage Form (FDF) pharmaceuticals, and Aesthetic & Cosmetic Ingredients. The company has established advanced technology platforms including Flow Chemistry, Synthetic Biology & Biocatalysis, Crystallization & Particle Engineering, Peptide synthesis, High Potency Compounds, Oligonucleotide Synthesis, Controlled-release Formulations, and Taste Masking Technologies. The company also operates analytical testing and process safety laboratories to support comprehensive pharmaceutical development and manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• 天立威 (Tianliwei): Antibiotic product line including oral cephalosporin series
• 百士欣 (Baishixin)
• 优胜美特 (Youshengmeite)
• 立安 (Lian)

Products and services

• API & Intermediates (原料药及中间体) Manufacture and sale of active pharmaceutical ingredients and intermediates — covering both chemical synthesis and biological fermentation domains — supplied to global pharmaceutical companies for use in commercial drug products. Sales driven by GMP-compliant, FDA-inspected manufacturing facilities.
• CDMO Services (创新药研发生产服务) End-to-end Contract Development and Manufacturing Organization services for innovative drugs, providing process development, clinical trial supply, and commercial manufacturing from early-stage R&D through commercial production for biotech and innovative drug developers worldwide.
• Finished Dosage Form (药品) Development and manufacture of finished pharmaceutical products including tablets, capsules, injections, and topical formulations across CNS, cardiovascular, anti-infective, and digestive therapeutic areas; both prescription and OTC products. Includes Tianliwei antibiotic line and Lian antiviral line, leveraging API-drug vertical integration.
• Aesthetic & Cosmetic Ingredients (医美及化妆品原料) R&D, production, and sale of medical aesthetic and cosmetic raw materials, leveraging advanced synthetic biology and peptide technology platforms, providing customized ingredients and consistent quality supply to leading global cosmetics companies.

Quantifiable outcome

• Ranked 5th among China's small molecule CDMO enterprises
• +2 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

18 partnerships are on record, tiered strategic, minor, major and core.

• 金华金控/百花医药 (Jinhua Financial Holdings/Baihua Pharmaceutical)strategicOthers · 1 June 2026Exploration of state-owned capital and industrial enterprise cooperation to promote regional pharmaceutical industry development. Jinhua Financial Holdings recently acquired Baihua Pharmaceutical's subsidiary Nanjing Huawei Pharmaceutical.
• 浙江师范大学 (Zhejiang Normal University)minorOthers · 1 June 2019University-industry cooperation for talent development and recruitment. Company provides internship platform and career opportunities for university students.
• 长三角G60科创走廊生物医药产业联盟 (G60 Bio-Pharma Industry Alliance)majorOthers · 1 June 2019Vice chairman unit of the alliance established by Shanghai, Zhejiang, Jiangsu, Anhui provinces for coordinated bio-pharmaceutical industry development.
• 海创药业 (Hionext)coreStrategic or Co-development PartnerLong-term CDMO cooperation with annual 'Excellent Cooperation Supplier' recognition for 3 consecutive years. Partnership involves development and manufacturing services for innovative drugs.
• 和黄医药 (Hutchmed)coreStrategic or Co-development PartnerStrategic partnership for CDMO services with recognition as 'Best Innovation Partner'. Collaboration on innovative drug development and manufacturing.
• 泽璟制药 (Zhejin Pharmaceutical)coreStrategic or Co-development PartnerStrategic CDMO cooperation agreement for drug development and manufacturing services.
• 先声药业 (Simcere Pharmaceutical)coreStrategic or Co-development PartnerLong-term strategic CDMO cooperation framework agreement for innovative drug development and manufacturing.
• 安帝康生物 (Andaikang Biological)majorStrategic or Co-development PartnerStrategic cooperation partnership for pharmaceutical development and manufacturing services.
• 德睿智药 (DreamMedic)majorStrategic or Co-development PartnerStrategic cooperation agreement leveraging AI and innovative drug development capabilities.
• 百葵锐生物 (Baikuicui Biotechnology)majorStrategic or Co-development PartnerStrategic cooperation in synthetic biology and biotechnology development.
• 海金格 (Haijingge Clinical Research)majorStrategic or Co-development PartnerClinical cooperation partnership for weight loss and diabetes GLP-1 drug project.
• 臻格生物 (Zhengbio)majorStrategic or Co-development PartnerStrategic cooperation agreement for biopharmaceutical development and manufacturing.
• 巴斯夫 (BASF)coreStrategic or Co-development PartnerStrategic cooperation under Hengdian Group-BASF framework. Collaboration areas include specialty excipients development, catalyst development, continuous manufacturing, process safety, automation and digitalization, and intelligent factory design.
• 岛津 (Shimadzu)majorTechnology or IntegrationJoint laboratory cooperation with Shimadzu Corporation for pharmaceutical R&D and analytical testing technology advancement.
• MPP (Medicines Patent Pool)majorOthersLicense agreement with MPP to produce and supply Pfizer's oral COVID-19 treatment to 95 low- and middle-income countries.
• 横店集团 (Hengdian Group)coreOthersParent company - Hengdian Group is a diversified conglomerate with total assets exceeding 70 billion RMB, providing strategic guidance and corporate governance.
• 山东罗欣药业 (Shandong Luoxin)majorChannel Partner/ Reseller/ DistributorStrategic partnership for API supply and international market expansion cooperation.
• 四川科伦药业 (Sichuan Kelun Pharmaceutical)majorChannel Partner/ Reseller/ DistributorStrategic API supply partnership and market development cooperation.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Asymchem Laboratories: China-based leading small-molecule CDMO with comparable API/intermediate manufacturing and end-to-end development services. Directly competes with Apeloa for global pharma CDMO contracts at similar scale.
• Shenzhen Hepalink Pharmaceutical: China-based API and intermediates manufacturer with significant heparin API exports. Comparable to Apeloa in API export scale, global regulatory standing, and China-listed public-company profile.
• Zhejiang Huahai Pharmaceutical: China-based API and finished dosage manufacturer with strong FDA-cleared facilities and a global generic and CDMO footprint. Closely comparable to Apeloa in API commercial manufacturing, regulatory profile, and Chinese export rankings.
• Livzon Pharmaceutical Group: China-listed integrated pharmaceutical company combining API/intermediate manufacturing with finished dosage forms and biologics. Mirrors Apeloa's four-pillar structure (API, CDMO, FDF, specialty ingredients).
• Pharmaron: China-headquartered, Hong Kong-listed CDMO offering integrated drug discovery, development, and manufacturing services. Directly comparable to Apeloa in small-molecule CDMO with overlapping global pharma client base.

Broad incumbents

• China Resources Pharmaceutical Group: Large state-owned Chinese pharmaceutical group spanning API manufacturing, finished drugs, and distribution. Overlaps with Apeloa's domestic FDF and distribution channels rather than its CDMO focus.
• Shanghai Pharmaceuticals Holding: State-owned Chinese pharmaceutical conglomerate with API manufacturing, CDMO services, and a large domestic drug distribution network. Provides broad-incumbent competitive context for Apeloa's domestic drug business.
• WuXi STA (WuXi AppTec): Largest Chinese CDMO and part of WuXi AppTec's CXO platform. Operates at materially larger scale than Apeloa across small-molecule API, drug product, and increasingly peptides/oligonucleotides — the dominant competitive benchmark.
• CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharma with API manufacturing, innovative drug R&D, and finished formulations. Competes with Apeloa for talent and for domestic Chinese pharmaceutical market share, particularly in CNS and anti-infective therapeutic areas.

Emerging players

• WuXi Biologics: Global biologics CDMO with established Hong Kong listing. Partial overlap with Apeloa where the company expands into oligonucleotide and bioconjugate manufacturing; competes for the same biotech CDMO wallet.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/apeloa-pharmaceutical-co-ltd

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apeloa Pharmaceutical